RxDoctor Payments Data

Hans Jeppesen, MD

Internal Medicine · Salem, MANPI 1669678298

Payments from drug & device makers

$828in general payments, 2019–2025

Across 40 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$155
  • Novartis$138
  • GSK$135
  • Indivior Inc.$100
  • AstraZeneca$92
  • Amgen$61
  • plus $147 from 5 others

What the payments were for

  • Food & beverage$828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$828 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$146,411
Medicare patients
698
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban717$200,261
XareltoRivaroxaban212$60,889
OzempicSemaglutide55$53,467
NuplazidPimavanserin Tartrate22$53,334
JardianceEmpagliflozin91$34,404
TrulicityDulaglutide49$33,917
XifaxanRifaximin18$26,383
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,743
Rufinamide13$12,575
Breo ElliptaFluticasone/Vilanterol24$12,441
SantylCollagenase Clostridium Hist.25$11,064
Gabapentin504$10,667
JanuviaSitagliptin Phosphate35$10,237
Atorvastatin Calcium755$9,647
Mirtazapine435$8,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$200,261717 claims
Novo NordiskOzempic$155$53,46755 claims
Boehringer IngelheimJardiance, Combivent Respimat$33$42,498106 claims
Lilly USA, LLCTrulicity$38$33,91749 claims
GSKTrelegy Ellipta, Breo Ellipta$135$28,18444 claims
AstraZenecaLokelma$92$6,50918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Salem

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →